Evidence map›Paper›PMID 27926867›Full record

ArticleCell reports2016

Genomic Instability Is Induced by Persistent Proliferation of Cells Undergoing Epithelial-to-Mesenchymal Transition.

Valentine Comaills, Lilian Kabeche, Robert Morris, Rémi Buisson, Min Yu, Marissa Wells Madden, Joseph A LiCausi, Myriam Boukhali, Ken Tajima, Shiwei Pan and 13 more

Open access · goldAbstract read
In one paragraph

Article in Cell reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 84 papers.

0numbers the graph read from it
0cells of the map it votes in
84citing papers in PubMed
5.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

84 citing papers in PubMed, 131 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Epithelial-to-mesenchymal transition drives cancer genomic instability.Journal of experimental & clinical cancer research : CR · 2025
    Article
  11. Article
  12. Article
  13. Review
  14. Chromosomal Instability and Chromoanagenesis as Forces for Genomic Evolution.Methods in molecular biology (Clifton, N.J.) · 2025
    Review
  15. Emerin expression stratification across breast cancer subtypes.Cancer treatment and research communications · 2025
    Article
  16. Article
  17. Article
  18. Emerin deficiency drives MCF7 cells to an invasive phenotype.bioRxiv : the preprint server for biology · 2024
    Article
  19. Article
  20. Article

24 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 2 institutions in 1 country.

Valentine ComaillsMassachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA; Department of Surgery, Harvard Medical School, Charlestown, MA 02129, USA.
Lilian KabecheMassachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA.
Robert MorrisMassachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA.
Rémi BuissonMassachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA.
Min YuMassachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA.
Marissa Wells MaddenMassachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA.
Joseph A LiCausiMassachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA.
Myriam BoukhaliMassachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA.
Ken TajimaMassachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA; Department of Surgery, Harvard Medical School, Charlestown, MA 02129, USA.
Shiwei PanMassachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA.
Nicola AcetoMassachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA.
Srinjoy SilMassachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA.
Yu ZhengMassachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA; Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA.
Tilak SundaresanMassachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA; Department of Medicine, Harvard Medical School, Charlestown, MA 02129, USA.
Toshifumi YaeMassachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA; Department of Surgery, Harvard Medical School, Charlestown, MA 02129, USA.
Nicole Vincent JordanMassachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA; Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA.
David T MiyamotoMassachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA; Department of Medicine, Harvard Medical School, Charlestown, MA 02129, USA.
David T TingMassachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA; Department of Medicine, Harvard Medical School, Charlestown, MA 02129, USA.
Sridhar RamaswamyMassachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA; Department of Medicine, Harvard Medical School, Charlestown, MA 02129, USA.
Wilhelm HaasMassachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA.
Lee ZouMassachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA; Department of Pathology, Harvard Medical School, Charlestown, MA 02129, USA.
Daniel A HaberMassachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA; Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA; Department of Medicine, Harvard Medical School, Charlestown, MA 02129, USA.
Shyamala MaheswaranMassachusetts General Hospital Cancer Center, Harvard Medical School, Charlestown, MA 02129, USA; Department of Surgery, Harvard Medical School, Charlestown, MA 02129, USA. Electronic address: maheswaran@helix.mgh.harvard.edu.
Harvard University · USMassachusetts General Hospital · US

Funding

MOLECULAR IMMUNOLOGY AND TUMOR BIOLOGYT32CA009216 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI David Michael Langenau · 1985 to 2026
$10.6M
Modeling Metastasis and Acquired Drug Resistance Using Circulating Tumor CellsR01CA129933 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Daniel A. Haber · 2008 to 2026
$7.5M
Regulation of the ATR Checkpoint Kinase by DNA DamageR01GM076388 · NIGMS · MASSACHUSETTS GENERAL HOSPITAL · PI ZOU, LEE · 2006 to 2018
$4.3M
Howard Hughes Medical InstituteNCI NIH HHS R01 CA129933NCI NIH HHS T32 CA009216NIGMS NIH HHS R01 GM076388
6 · The paper itself

Abstract

TGF-β secreted by tumor stroma induces epithelial-to-mesenchymal transition (EMT) in cancer cells, a reversible phenotype linked to cancer progression and drug resistance. However, exposure to stromal signals may also lead to heritable changes in cancer cells, which are poorly understood. We show that epithelial cells failing to undergo proliferation arrest during TGF-β-induced EMT sustain mitotic abnormalities due to failed cytokinesis, resulting in aneuploidy. This genomic instability is associated with the suppression of multiple nuclear envelope proteins implicated in mitotic regulation and is phenocopied by modulating the expression of LaminB1. While TGF-β-induced mitotic defects in proliferating cells are reversible upon its withdrawal, the acquired genomic abnormalities persist, leading to increased tumorigenic phenotypes. In metastatic breast cancer patients, increased mesenchymal marker expression within single circulating tumor cells is correlated with genomic instability. These observations identify a mechanism whereby microenvironment-derived signals trigger heritable genetic changes within cancer cells, contributing to tumor evolution.

Indexed as

Breast NeoplasmsCell DifferentiationCell Line, TumorCell ProliferationEpithelial-Mesenchymal TransitionFemaleGenomic InstabilityHumansLamin Type BTransforming Growth Factor beta1Lamin Type BTransforming Growth Factor beta1

Identifiers

PMID27926867
PMCPMC5320932
OpenAlexW2560567639

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.